Low-grade Gliomas
Conditions
Brief summary
This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who have failed initial conventional treatment. In addition to evaluating the toxicity of this drug regimen, the potential efficacy of the regimen will be assessed.
Interventions
DRUGTarceva and Rapamycin
Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
Sponsors
Children's National Research Institute
Roger Packer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* children less than 21 years of age, with or without neurofibromatosis, with recurrent low-grade gliomas. * patients with or without NF1 must have failed some form of conventional therapy, radiotherapy, or chemotherapy (carboplatin/vincristine) to be eligible, including those treated wtih initial surgery. Patients do not have to have received radiotherapy to be eligible. * children with all types of histologically proven low-grade gliomas will be eligible; re-operation at the time of recurrence is not mandatory for entry on study. * patients with intrinsic brain lesions, believed neuroradiographically consistent with a low-grade glial tumor, with neurofibromatosis type 1 can be treated without histological confirmation. * patients without neurofibromatosis type 1 must have histological confirmation of a low-grade glial tumor prior to entry on study. * patients must have a Karnofsky score of greater than or equal to 50% for children greater than 10 years of age, or a Lansky score of greater than or equal to 50% for patients less than 10 years of age. * patients who are unable to walk because of paralysis, but who are able to use a wheelchair, will be considered ambulatory for purposes of assessing performance score. * patients must have a life expectancy of at least 12 weeks. * patients must be able to swallow medication in tablet form. * patients must have adequate organ function, including: peripheral ANC of greater than 1,000/microliters; a platelet count of greater than 100,000/microliters; hemoglobin of greater than 8 gms,dl (pRBC transfusions of allowed to maintain hemoglobin \> 8 g/dl) * patients must have adequate renal function, which is defined as a normal serum creatinine for age * patients must have adequate liver function, as defined as a total bilirubin or less than 1.5 times the upper limit of normal for age, and an SGPT (ALT) of less than 2.5 times the upper limit of normal for age * patients must have had a MR scan within 3 weeks of starting treatment * all patients, and/or their parents or legal guardian, must sign a recent informed consent * all institutional, FDA, and NCI requirements for human study must be met.
Exclusion criteria
* patients must not have any other active tumors. * pregnancy or breast feeding is an
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participants will remain on the trial for one year if benefiting from drug as demonstrated by radiographic evaluation and clinical evaluation. | one year |
Countries
United States
Outcome results
None listed